Ignite Creation Date:
2025-12-26 @ 10:44 PM
Ignite Modification Date:
2025-12-26 @ 10:44 PM
Study NCT ID:
NCT02498912
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-07-31
First Post:
2015-07-10
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Solid Tumors
Sponsor:
Memorial Sloan Kettering Cancer Center
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2015-08
Start Date Type:
ACTUAL
Primary Completion Date:
2026-08
Primary Completion Date Type:
ESTIMATED
Completion Date:
2026-08
Completion Date Type:
ESTIMATED
First Submit Date:
2015-07-10
First Submit QC Date:
None
Study First Post Date:
2015-07-15
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-07-30
Last Update Post Date:
2025-07-31
Last Update Post Date Type:
ACTUAL